In Brief: FTC prioritizes deceptive health claims; NAD rules on Farr, Migralex ads; Tainted weight-loss supplements; Atrium adds Russian distributor
This article was originally published in The Tan Sheet
Executive Summary
Deceptive health claims among FTC priorities; drugs in weight loss supplements; Farr modifies Prosta-Q claims; Migralex supports headache relief claims; Atrium acquires Russian distributor; GNC scores discount supplements; and J&J reopens baby powder plant in India